Is JNJ or NSRX more undervalued in 2026?

CirclFi compares Johnson & Johnson (JNJ) and Nasus Pharma Ltd. (NSRX) using 13 institutional-grade valuation models. JNJ has a Quality of Company score of 9.7/10 while NSRX scores 1.9/10.

Which is a better buy — JNJ or NSRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do JNJ and NSRX valuations compare?

JNJ at $230.80 and NSRX at $3.20 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

JNJ vs NSRX Valuation Comparison 2026 — Intrinsic Value Analysis

JNJ

Drug Manufacturers - General

Johnson & Johnson

Quality

9.7

out of 10

Value Trap

SAFE

Price

$230.80

Last close

Models

12/13

Active

NSRX

Drug Manufacturers - General

Nasus Pharma Ltd.

Quality

1.9

out of 10

Value Trap

—

Price

$3.20

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	JNJ Fair Value	JNJ Upside	NSRX Fair Value	NSRX Upside
Bayesian DCF	Intrinsic	$76.94	-66.7%	$0.85	-73.5%
Earnings Power Value	Intrinsic	$50.60	-78.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$245.78	+6.5%	$2.27	-24.8%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for JNJ vs NSRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JNJ vs NSRX — Which Stock Is More Undervalued?

JNJ scores higher with a 9.7/10 quality rating vs NSRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Johnson & Johnson (JNJ) and Nasus Pharma Ltd. (NSRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JNJ currently trades at $230.80 with a QOC of 9.7/10, while NSRX trades at $3.20 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).